Key result
Acipimox reduced circulating free fatty acids by 27% compared to placebo (change -0.10 vs +0.01 mmol/l, P<0.01) but did not improve systolic or diastolic cardiac function or exercise capacity.
Why the study?
Does acipimox improve cardiac function or exercise capacity in patients with chronic heart failure?
Population
24 patients with chronic heart failure and ischemic heart disease. 18 patients were included for analysis.
Comparison
Acipimox 250 mg, 4 times/day for 28 days vs Placebo for 28 days
Design
RCT, randomized crossover design, double-blind
Follow-up
28 days
Authors
Loading...
Does not improve cardiac function or exercise capacity in chronic HF despite lowering free fatty acids; challenges metabolic modulation as a therapeutic target.
RCT (n=24)
Double-blind
Crossover
Does acipimox improve cardiac function or exercise capacity in patients with chronic heart failure?
Absolute Event Rate: -0.1% vs 0.01%
p-value: p=< 0.01
In patients with chronic heart failure, reducing circulating free fatty acids with acipimox for 28 days alters whole body metabolism but fails to improve cardiac function or exercise capacity.
Halbirk et al. (2010) conducted an RCT in Chronic heart failure (n=24). Acipimox vs. Placebo was evaluated on Change in circulating free fatty acids (mmol/l) from day 0 to day 28 (p=< 0.01). Acipimox reduced circulating free fatty acids by 27% compared to placebo (change -0.10 vs +0.01 mmol/l, P<0.01) but did not improve systolic or diastolic cardiac function or exercise capacity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: